<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03290534</url>
  </required_header>
  <id_info>
    <org_study_id>CT006</org_study_id>
    <nct_id>NCT03290534</nct_id>
  </id_info>
  <brief_title>Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®</brief_title>
  <official_title>Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CivaTech Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NIH/NCI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CivaTech Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study to determine the usefulness of a brachytherapy device that
      utilizes active components (palladium-103) of standard devices in a novel configuration,
      which may benefit lung cancer patients by reducing the radiation dose to critical structures,
      such as the heart wall, while giving a therapeutic dose to diseased tissue, such as at a
      surgical margin.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local Control Rate at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>The local control rate in the region irradiated by CivaSheet.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from regional or distant recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Control rate for recurrences outside the local area irradiated by CivaSheet.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Time in months to any recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity graded on CTCAE 4.0 Scale</measure>
    <time_frame>1 year</time_frame>
    <description>pulmonary function, radiation pneumonitis, fatigue, lung fibrosis, etc.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Cancer Stage I</condition>
  <condition>Lung Cancer Stage II</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CivaSheet</intervention_name>
    <description>implanting CivaSheet for localized radiation dose delivery</description>
    <other_name>brachytherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject signed inform consent

          -  Suspected or proven non-small cell lung cancer (NSCLC) in the upper lobes of the left
             or right lung

          -  Pre-operative criteria

          -  Lung nodule suspicious for NSCLC

          -  Mass ≤ 7 cm in maximum diameter by CT scan of the chest and upper abdomen

          -  Clinical stage I or Clinical stage II

          -  Not pregnant or nursing

          -  Negative pregnancy test in premenopausal women

          -  Fertile patients must use effective contraception

          -  More than 5 years since prior invasive malignancy unless non melanoma skin cancer or
             in-situ cancer

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carra Castagnero</last_name>
    <phone>9193145515</phone>
    <email>clinical@civatechoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristy Perez, PhD</last_name>
    <phone>6789545744</phone>
    <email>kperez@civatechoncology.com</email>
  </overall_contact_backup>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2017</study_first_posted>
  <last_update_submitted>September 22, 2017</last_update_submitted>
  <last_update_submitted_qc>September 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wedge resection</keyword>
  <keyword>sublobar resection</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>CivaSheet</keyword>
  <keyword>Pd-103</keyword>
  <keyword>CivaTech Oncology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

